Strategy Suggests Combining Surrogate Markers for Kidney Disease Progression in Clinical Trials
American Society of Nephrology (ASN)In clinical trials of patients with chronic kidney disease, combining information from the treatment effects on two markers of kidney disease progression—urinary albumin:creatinine ratio change and glomerular filtration rate slope—improves predictions of treatment effects on clinical endpoints.